About This Article
An article published in Diabetes, Obesity and Metabolism, co-authored by Glyscend Therapeutics and ProSciento, discusses findings from a study that examined the effects of GLY-200, an oral pharmacologic duodenal exclusion drug, in patients with type 2 diabetes and obesity. The study demonstrated significant improvements in glucose control, lipid profiles, and body weight, highlighting GLY-200’s potential as a non-invasive therapeutic option for managing metabolic diseases.
